Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy

Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospecti...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Endocrinol (Lausanne)
Asıl Yazarlar: Grisanti, Salvatore, Cosentini, Deborah, Laganà, Marta, Morandi, Alessandra, Lazzari, Barbara, Ferrari, Laura, Volta, Alberto Dalla, Ambrosini, Roberta, Ferrari, Vittorio Domenico, Sigala, Sandra, Berruti, Alfredo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Endocrinology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7943871/
https://ncbi.nlm.nih.gov/pubmed/33716976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.624102
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller